Published in Medical Letter on the CDC and FDA, September 26th, 2004
Spectral received a license from the U.S. Centers for Disease Control for use of their reagents to develop a rapid assay for exposure to the West Nile Virus. Spectral's assay detects a patient's response to the West Nile Virus and is most useful for the many patients who present with nonspecific flu-like symptoms following recent exposure to potentially infected mosquitoes.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA